Viruses and tumours--an update.

In the 40 years since the publication of the article by Harris (Eur J Cancer 1965, 1, 183-188), considerable progress has been made towards the understanding of the contribution of infectious agents to the development of tumours. It is estimated that 15-20% of human malignancies may have an infectious aetiology. This article attempts to summarise the current level of our knowledge with respect to tumour-associated viruses, and to place this in the context of the earlier article by Harris (Eur J Cancer 1965, 1, 183-188).

[1]  John D. Minna,et al.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma , 1980, Proceedings of the National Academy of Sciences.

[2]  M. Lipinski,et al.  Isolation of a normal B cell subset with a Burkitt‐like phenotype and transformation in vitro with Epstein‐Barr virus , 1988, International journal of cancer.

[3]  M. Wigler,et al.  Cloning the differences between two complex genomes , 1993, Science.

[4]  M. Sadelain,et al.  Occurrence of leukaemia following gene therapy of X-linked SCID , 2003, Nature Reviews Cancer.

[5]  E. Cesarman,et al.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. , 1994, Science.

[6]  C. von Kalle,et al.  Murine Leukemia Induced by Retroviral Gene Marking , 2002, Science.

[7]  D. Crawford,et al.  The role of EBV in post-transplant malignancies: a review , 2000, Journal of clinical pathology.

[8]  P. L. Deininger,et al.  DNA sequence and expression of the B95-8 Epstein—Barr virus genome , 1984, Nature.

[9]  V. Beral,et al.  Overview of the epidemiology of immunodeficiency-associated cancers. , 1998, Journal of the National Cancer Institute. Monographs.

[10]  Y. Shiratori,et al.  Hepatitis C Virus Core Protein Enhances p53 Function through Augmentation of DNA Binding Affinity and Transcriptional Ability* , 2000, The Journal of Biological Chemistry.

[11]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[12]  D. Burkitt,et al.  A sarcoma involving the jaws in african children , 1958, CA: a cancer journal for clinicians.

[13]  M. Yoshida,et al.  Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. , 2001, Annual review of immunology.

[14]  LJ Kinlen,et al.  Infective cause of childhood leukaemia and wartime population mixing in Orkney and Shetland, UK , 2001, The Lancet.

[15]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[16]  A. Rickinson,et al.  Epstein–Barr virus–associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2 , 2002, Nature Medicine.

[17]  G. Nabel,et al.  p53 inhibition by the LANA protein of KSHV protects against cell death , 1999, Nature.

[18]  S. Maruo,et al.  Oncogenic Role of Epstein-Barr Virus-Encoded RNAs in Burkitt’s Lymphoma Cell Line Akata , 1999, Journal of Virology.

[19]  M. Houghton,et al.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.

[20]  D. Crawford,et al.  THE ROLE OF ADOPTIVE IMMUNOTHERAPY IN THE PREVENTION AND TREATMENT OF LYMPHOPROLIFERATIVE DISEASE FOLLOWING TRANSPLANTATION , 1999, British journal of haematology.

[21]  L. Kinlen.  Infection and childhood leukemia. , 1998, Cancer causes & control : CCC.

[22]  N. Raab-Traub,et al.  The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation , 1986, Cell.

[23]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[24]  R. Tjian,et al.  Enzymatic activities associated with a purified simian virus 40 T antigen-related protein. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Swerdlow,et al.  Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells , 2002, The Lancet.

[26]  Kaposi,et al.  Idiopathisches multiples Pigmentsarkom der Haut , 1872, Archiv für Dermatologie und Syphilis.

[27]  Eero Pukkala,et al.  Cancer risk after renal transplantation in the nordic countries, 1964–1986 , 1995, International journal of cancer.

[28]  Malcolm K. Brenner,et al.  Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes , 1996, Nature Medicine.

[29]  L. Young,et al.  The expression and function of Epstein-Barr virus encoded latent genes , 2000, Molecular pathology : MP.

[30]  R. Krance,et al.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation , 1995, The Lancet.

[31]  H L Robinson,et al.  Acceptor sites for retroviral integrations map near DNase I-hypersensitive sites in chromatin , 1986, Journal of virology.

[32]  C. Ford,et al.  Mouse mammary tumor virus-like gene sequences in breast tumors of Australian and Vietnamese women. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  N. Day,et al.  Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study , 1978, Nature.

[34]  R. Zeillinger,et al.  The mouse mammary tumor virus-like env gene sequence is not detectable in breast cancer tissue of Austrian patients. , 2003, Oncology reports.

[35]  F. Deinhardt,et al.  Comparative Aspects: Oncogenic Animal Herpesviruses , 1979 .

[36]  R. Doll,et al.  Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. , 1979, British medical journal.

[37]  M. Ballestas,et al.  Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. , 1999, Science.

[38]  C. Boshoff,et al.  The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma–E2F pathway and with the oncogene Hras transforms primary rat cells , 2000, Nature Medicine.

[39]  J. Yates,et al.  Stable replication of plasmids derived from Epstein–Barr virus in various mammalian cells , 1985, Nature.

[40]  D. Burkitt.  Determining the Climatic Limitations of a Children's Cancer Common in Africa , 1962, British medical journal.

[41]  I. Penn.  The changing pattern of posttransplant malignancies. , 1991, Transplantation proceedings.

[42]  S. Mizutani,et al.  Viral RNA-dependent DNA Polymerase: RNA-dependent DNA Polymerase in Virions of Rous Sarcoma Virus , 1970, Nature.

[43]  Frederick Y. Wu,et al.  A novel viral mechanism for dysregulation of β-catenin in Kaposi's sarcoma–associated herpesvirus latency , 2003, Nature Medicine.

[44]  J. H. Pope,et al.  Transformation of foetal human leukocytes in vitro by filtrates of a human leukaemic cell line containing herpes‐like virus , 1968 .

[45]  M. Epstein,et al.  The Epstein-Barr Virus , 1979, Springer Berlin Heidelberg.

[46]  D. Baltimore.  Viral RNA-dependent DNA Polymerase: RNA-dependent DNA Polymerase in Virions of RNA Tumour Viruses , 1970, Nature.

[47]  H J Alter,et al.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. , 2000, Science.

[48]  T. Crook,et al.  p53 is frequently mutated in Burkitt's lymphoma cell lines. , 1991, The EMBO journal.

[49]  M. Epstein,et al.  VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. , 1964, Lancet.

[50]  C. Stiller,et al.  Childhood leukaemia and non-Hodgkin's lymphoma near large rural construction sites, with a comparison with Sellafield nuclear site , 1995, BMJ.

[51]  W. Ludwig,et al.  TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). , 1991, Oncogene.

[52]  R. J. Harris.  Viruses and tumours. , 1965, European journal of cancer.

[53]  W. Hammerschmidt,et al.  Molecular virology of Epstein-Barr virus. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[54]  H. Temin.  Genetic and possible biochemical mechanisms in viral carcinogenesis. , 1966, Cancer research.

[55]  L. Young,et al.  Differences in B cell growth phenotype reflect novel patterns of Epstein‐Barr virus latent gene expression in Burkitt's lymphoma cells. , 1987, The EMBO journal.

[56]  E. Wattel,et al.  Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo , 2003, Leukemia.

[57]  G. Klein,et al.  Characteristic chromosomal abnormalities in biopsies and lymphoid‐cell lines from patients with burkitt and non‐burkitt lymphomas , 1976, International journal of cancer.

[58]  F. Deist,et al.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.